EyeBio a London Biotech business co-founded by Britain’s vaccine tsar Kate Bingham, has been bought by Merck, US company, In UK MSD and would pay £1bn ($1.3bn)  with a further $1.7bn expected if certain targets are met.

Eyebio raised $130m, its found Dame Kate said “ It’s astonishing  to have achieved such a high valuation in such a short space of time”. Her Venture Capital firm SV Health  Investors  setup the business together  with scientists David Guyer and Tony Admis in August 2021.

Fifty-eight- year-old  Dame Kate was among the leading architects for Britain’s Covid vaccine rollout during the pandemic. She steered UK’s Vaccine Taskforce  in early 2020 and was given damehood  in recognition of her success in acquiring Covid-19 vaccines, effectively making UK the first western country to start vaccinating citizens in late 2020.